Pyxis Oncology, Inc.
General ticker "PYXS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $100.3M (TTM average)
Pyxis Oncology, Inc. follows the US Stock Market performance with the rate: 44.5%.
Estimated limits based on current volatility of 8.9%: low 3.98$, high 4.76$
Factors to consider:
- Total employees count: 44 (-12.0%) as of 2024
- Top business risk factors: Operational and conduct risks, Clinical development risks, Liquidity and credit risks, Regulatory and compliance, Labor/talent shortage/retention
- Current price 39.8% above estimated high
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.02$, 3.09$]
- 2025-12-31 to 2026-12-31 estimated range: [0.88$, 2.62$]
Financial Metrics affecting the PYXS estimates:
- Positive: with PPE of -1.6 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -61.89 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 76.82 > 63.39
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Negative: negative Net income
Short-term PYXS quotes
Long-term PYXS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $16.15MM |
| Operating Expenses | $123.48MM | $82.20MM | $105.61MM |
| Operating Income | $-123.48MM | $-82.20MM | $-89.46MM |
| Non-Operating Income | $2.76MM | $8.41MM | $9.96MM |
| R&D Expense | $86.13MM | $49.59MM | $58.75MM |
| Income(Loss) | $-120.72MM | $-73.79MM | $-79.50MM |
| Taxes | $0.00MM | $0.00MM | $-2.16MM |
| Profit(Loss)* | $-120.72MM | $-73.79MM | $-77.33MM |
| Stockholders Equity | $160.82MM | $125.70MM | $120.75MM |
| Assets | $211.38MM | $173.73MM | $157.18MM |
| Operating Cash Flow | $-89.33MM | $-70.71MM | $-57.67MM |
| Capital expenditure | $6.40MM | $6.73MM | $0.24MM |
| Investing Cash Flow | $-6.40MM | $-104.85MM | $8.15MM |
| Financing Cash Flow | $0.18MM | $5.93MM | $59.33MM |
| Earnings Per Share** | $-3.65 | $-1.85 | $-1.32 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.